Skip to main content

Table 3 Outcomes for placebo controlled trials in bipolar mania (<6 weeks and 6–12 weeks)

From: Atypical antipsychotics in bipolar disorder: systematic review of randomised trials

   Events/total patients Event rate (%)   
Outcome Trials Treatment Placebo Treatment Placebo Relative Risk (95% CI) NNT (95% CI)
Less than 6 weeks [24, 26, 28, 29, 31-38, 42, 43]        
Efficacy        
Response        
All mono- and adjunctive therapy 14 845/1634 473/1467 52 32 1.6 (1.5 to 1.8) 5.1 (4.4 to 6.2)
All monotherapy only 8 486/949 234/791 51 30 1.7 (1.5 to 2.0) 4.6 (3.8 to 5.8)
Olanzapine 2 69/125 41/129 55 32 1.8 (1.3 to 2.4) 4.3 (2.8 to 8.7)
Risperidone 4 276/502 157/478 55 33 1.7 (1.5 to 2.0) 4.5 (3.6 to 6.2)
Quetiapine 4 247/474 167/469 52 36 1.5 (1.3 to 1.7) 6.1 (4.4 to 9.8)
Aripiprazole 2 123/263 66/259 47 25 1.8 (1.4 to 2.3) 4.7 (3.4 to 7.6)
Symptomatic remission        
All mono- and adjunctive therapy 4 210/448 128/453 47 28 1.7 (1.4 to 2.0) 5.4 (4.0 to 8.1)
All monotherapy only 2 83/182 44/179 46 25 1.9 (1.4 to 2.5) 4.8 (3.3 to 8.8)
Emergence of depression        
Quetiapine, plus mood stabiliser 2 33/275 30/285 12 11 1.2 (0.7 to 1.8) not calculated
Discontinuations        
All cause 13 513/1507 613/1350 34 45 0.7 (0.7 to 0.8) 8.8 (6.7 to 13)
Lack of efficacy 13 187/1507 306/1350 12 23 0.5 (0.5 to 0.6) 9.8 (7.7 to 13)
Adverse events 13 81/1507 66/1350 5.4 4.9 1.1 (0.8 to 1.5) not calculated
6 to 12 weeks [39, 42,43]        
Efficacy        
Response        
All mono- and adjunctive therapy 3 268/428 116/309 63 38 1.6 (1.4 to 1.9) 4.0 (3.1 to 5.6)
Symptomatic remission        
All mono- and adjunctive therapy 3 309/428 145/309 72 47 1.5 (1.3 to 1.7) 4.0 (3.1 to 5.5)
Emergence of depression        
All mono- and adjunctive therapy 2 9/208 17/197 8.6 4.3 0.5 (0.2 to 1.1) not calculated
Discontinuations        
All cause 3 151/438 154/313 34 49 0.8 (0.6 to 0.9) 6.8 (4.6 to 13)
Lack of efficacy 3 50/438 95/313 11 30 0.5 (0.3 to 0.6) 5.3 (4.0 to 7.7)
Adverse events 3 37/438 12/313 8.4 3.8 2.2 (1.1 to 4.4) 22 (13 to 80)
  1. For discontinuations NNTp is shown in bold, indicating fewer events with treatment than placebo. More events with treatment than placebo, NNH, is in plain text